Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study-Reference-Cited by-同舟云学术

Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study

Published:2023-03-14 Issue:1 Volume:26 Page:394-402
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Yousef Consuela Cheriece¹²³^ORCID,Khan Mansoor Ahmed⁴⁵⁶^ORCID,Almodaimegh Hind⁷⁸⁹^ORCID,Alshamrani Majed⁴⁵⁶^ORCID,Al-Foheidi Meteb⁵¹⁰¹¹^ORCID,AlAbdalkarim Hana⁹¹²¹³^ORCID,AlJedai Ahmed¹⁴¹⁵^ORCID,Naeem Anjum⁴⁵⁶^ORCID,Abraham Ivo¹⁶¹⁷^ORCID

Affiliation:

1. Pharmaceutical Care Department, Ministry of National Guard - Health Affairs, Dammam, Saudi Arabia

2. King Abdullah International Medical Research Center, Al Ahsa, Saudi Arabia

3. King Saud bin Abdul-Aziz University for Health Sciences, Al Ahsa, Saudi Arabia

4. Pharmaceutical Care Department, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia

5. King Abdullah International Medical Research Center, Jeddah, Saudi Arabia

6. King Saud bin Abdul-Aziz University for Health Sciences, Jeddah, Saudi Arabia

7. College of Pharmacy, King Saud bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia

8. Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia

9. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

10. College of Medicine, King Saud bin Abdul-Aziz University for Health Sciences, Jeddah, Saudi Arabia

11. Department of Oncology, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia

12. Drug Policy and Economic Center, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia

13. Doctoral School of Applied Informatics and Applied Mathematics, Obuda University, Budapest, Hungary

14. Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia

15. Colleges of Pharmacy and Medicine, Alfaisal University, Riyadh, Saudi Arabia

16. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

17. Matrix45, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2183680

Reference43 articles.

1. Biosimilars in 3D

2. Lybecker KM. The biologics revolution in the production of drugs [internet]. Intellect Prop Rights Promot Biol Med Devices Trade Pharm. 2016; [cited 2022 Apr 9]. p. 9. Available from: https://terzadecade.it/download/cellule_tempo_immortalita_-_quattro_storie_di_colture/Intellectual-Property-Rights-and-the-Promotion-of-Biologics-Medical-Devices-and-Trade-in-Pharmaceuticals.pdf#page=13

3. Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective

4. Evaluation of biosimilars for formulary inclusion: factors for consideration by P&T committees;Ventola CL.;P T,2015

5. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04

2. Preparing for the third decade of biosimilars;Expert Opinion on Biological Therapy;2023-08-03

3. The landscape of biosimilars in Saudi Arabia: preparing for the next decade;Expert Opinion on Biological Therapy;2023-07-28